Table 4.
Multiple Cox proportional hazard regression analysis of the relative risk of dying
| Variables | 0 to 4 months on ART | 5 to 12 months on ART | 13 to 24 months on ART | >24 months on ART | |||||
|---|---|---|---|---|---|---|---|---|---|
| co-eff (95% CI) | p-value | co-eff (95% CI) | p-value | co-eff (95% CI) | p-value | co-eff (95% CI) | p-value | ||
| Baseline CD4 cell count (cells/µL) | <50 | 2.09 (1.02 to 4.28) | 0.043 | 1.6 (0.84 to 3.06) | 0.152 | 1 (0.57 to 1.73) | 0.992 | 0.79 (0.51 to 1.22) | 0.279 |
| 50-199 | Referent | ||||||||
| Current CD4 cell count (cells/µL) | <50 | N/A | N/A | 1.89 (0.96 to 3.72) | 0.065 | 3.88 (2.03 to 7.41) | <0.001 | 3.54 (2.17 to 5.75) | <0.001 |
| 50-199 | Referent | ||||||||
| 200-349 | N/A | N/A | 0.58 (0.25 to 1.34) | 0.206 | 0.19 (0.06 to 0.55) | 0.002 | 0.74 (0.38 to 1.44) | 0.376 | |
| ≥350 | N/A | N/A | N/A | N/A | 0.36 (0.12 to 1.09) | 0.071 | 0.42 (0.15 to 1.17) | 0.098 | |
| ≥500 | N/A | N/A | N/A | N/A | N/A | N/A | 0.42 (0.15 to 1.23) | 0.115 | |
| Baseline viral load (copies/ml) | <100 000 | Referent | |||||||
| ≥100 000 | 2.12 (0.86 to 5.21) | 0.103 | 0.82 (0.44 to 1.53) | 0.541 | 1.34 (0.77 to 2.33) | 0.298 | 1.2 (0.78 to 1.85) | 0.413 | |
| Current viral load (copies/ml) | <400 | Referent | |||||||
| 400 – 9 999 | N/A | N/A | 1.09 (0.44 to 2.66) | 0.270 | 1.42 (0.57 to 3.59) | 0.967 | 1.32 (0.56 to 3.14) | 0.033 | |
| 10 000 – 99 999 | N/A | N/A | 0.64 (0.29 to 1.41) | 0.106 | 1.02 (0.44 to 2.36) | 0.394 | 2.24 (1.07 to 4.7) | 0.001 | |
| ≥100 000 | N/A | N/A | 1.76 (0.89 to 3.47) | 0.541 | 1.42 (0.63 to 3.2) | 0.298 | 3.6 (1.68 to 7.7) | 0.413 | |
| ART adherence (quartiles) | <42% | 2.14 (0.69 to 6.67) | 0.188 | 1.89 (1 to 3.57) | 0.049 | 1.40 (0.59 to 3.29) | 0.443 | 2.21 (0.87 to 5.63) | 0.096 |
| 42 to 75% | 3.18 (1.05 to 9.61) | 0.04 | 1.78 (0.92 to 3.43) | 0.086 | 0.65 (0.26 to 1.64) | 0.362 | 2.58 (1.04 to 6.39) | 0.041 | |
| 75 to 92% | N/A | N/A | 1.76 (0.9 to 3.46) | 0.098 | 0.91 (0.37 to 2.23) | 0.84 | 1.48 (0.56 to 3.91) | 0.427 | |
| >92% | Referent | ||||||||
| ARV regimen | First line | Referent | |||||||
| Second line | 6.39 (0.85 to 47.75) | 0.071 | 5.25 (2.11 to 13.06) | <0.001 | 1.4 (0.64 to 3.06) | 0.402 | 1.67 (1.09 to 2.56) | 0.018 | |
| NNRTI in first line | efavirenz | Referent | |||||||
| neviripine | 0.6 (0.28 to 1.26) | 0.175 | 1.26 (0.8 to 2) | 0.324 | 1.56 (0.85 to 2.85) | 0.149 | 0.89 (0.59 to 1.34) | 0.568 | |
| Duration of monitoring prior to starting ART (months) | ≥6 | Referent | |||||||
| <6 | 2.9 (0.28 to 1.26) | 0.296 | 1.15 (0.8 to 2) | 0.692 | 1.67 (0.85 to 2.85) | 0.328 | 1.05 (0.59 to 1.34) | 0.890 | |
| Sex | male | 0.79 (0.38 to 1.67) | 0.545 | 1 (0.68 to 1.46) | 0.998 | 1.15 (0.69 to 1.91) | 0.595 | 1.26 (0.85 to 1.86) | 0.257 |
| female | Referent | ||||||||
| Age at baseline (years) | <25 | 0.63 (0.15 to 2.7) | 0.531 | 2.06 (0.51 to 8.4) | 0.312 | 1.82 (0.25 to 13.22) | 0.555 | 2.15 (0.52 to 8.83) | 0.289 |
| 25-49 | Referent | ||||||||
| ≥50 | 1.69 (0.32 to 9.03) | 0.540 | 2.39 (0.52 to 10.98) | 0.263 | 1.34 (0.14 to 13.03) | 0.801 | 3.86 (0.81 to 18.35) | 0.090 | |